GlobeNewswire

Radisson Hospitality AB’s Q3 2019 report

Share

Third Quarter 2019

  • R evenue increased by MEUR 8.5 (3.4%) to MEUR 261.8. The increase is mainly due to the good like-for-like development and new openings. On a like-for-like basis, including hotels under renovation (“LFL&R”), Revenue increased as well by MEUR 8.5 (3.4%).
  • Reported RevPAR for leased and managed hotels increased by 3.4% and RevPAR LFL&R increased by 2.3%. The positive performance is driven both by the leased and the managed portfolio and particularly by the ramp up of hotels which were under renovation 2018 (5.5%).
  • EBITDA increased by MEUR 18.7 (46.5%) to MEUR 58.9 and the EBITDA margin increased 6.6 pp to 22.5%. The increase is mainly due to the implementation of the new accounting standard IFRS 16 Leases (MEUR 11.4) and lower net costs in central activities.
  • EBIT increased by MEUR 18.7 (94.4%) to MEUR 38.5, where of MEUR 4.7 is due to the implementation of IFRS 16 Leases. In addition, costs for write-downs were MEUR 7.0 lower than last year. The EBIT margin was 14.7% (7.8).
  • Profit/loss for the period increased by MEUR 12.3 (135.2%) to MEUR 21.4.
  • 2,660 (2,385) rooms were contracted, 1,064 (1,167) rooms opened and 83 (131) rooms left the system.


Nine months ended September 2019

  • Revenue increased by MEUR 23.9 (3.4%) to MEUR 737.1. Revenue LFL&R increased by MEUR 21.3 (3.0%).
  • Reported RevPAR for leased and managed hotels increased by 2.2% and RevPAR LFL&R increased by 1.8%.
  • EBITDA increased by MEUR 52.3 (60.3%) to MEUR 139.0 and the EBITDA margin increased 6.7 pp to 18.9%.
  • EBIT increased by MEUR 37.3 (88.6%) to MEUR 79.4 and the EBIT margin increased 4.9 pp to 10.8%.
  • Profit/loss for the period increased by MEUR 11.6 (47.2%) to MEUR 36.2.
  • Cash flow from operating activities amounted to MEUR 94.9 (81.6).
  • 9,394 (5,691) rooms were contracted, 3,278 (3,133) rooms opened and 1,404 (604) rooms left the system.


MEUR   Q3 2019 Q3 2018 Change % Jan-Sep 2019 Jan-Sep 2018 Change %
Revenue   261.8 253.3 8.5 3.4% 737.1 713.2 23.9 3.4%
EBITDA   58.9 40.2 18.7 46.5% 139.0 86.7 52.3 60.3%
EBITDA margin   22.5% 15.9% 6.6 pp   18.9% 12.2% 6.7 pp  
EBIT   38.5 19.8 18.7 94.4% 79.4 42.1 37.3 88.6%
EBIT margin   14.7% 7.8% 6.9 pp   10.8% 5.9% 4.9 pp  
Profit/loss for the period   21.4 9.1 12.3 135.2% 36.2 24.6 11.6 47.2%
Adjusted EBITDA   49.2 40.8 8.4 20.6% 107.3 87.5 19.8 22.6%
Adjusted EBITDA margin   18.8% 16.1% 2.7 pp   14.6% 12.3% 2.3 pp  
Adjusted EBIT   37.0 29.0 8.0 27.6% 71.2 52.7 18.5 35.1%
Adjusted EBIT margin   14.1% 11.4% 2.7 pp   9.7% 7.4% 2.3 pp  
Adjusted Profit/loss for the period   23.6 15.9 7.7 48.4% 40.3 32.5 7.8 24.0%


Comments from the CEO

Q3 2019 was another good quarter with strong EBITDA growth

More in detail, in the quarter we achieved an EBITDA of MEUR 58.9 (an increase of 46.5% and with 6.6 pp margin improvement). This is partly explained by the implementation of the new accounting standard for leases (IFRS 16), but nevertheless, the adjusted EBITDA increased 20.6% and the adjusted margin improved 2.7 pp. The quarter revenues show a 3.4% growth, with strong support from new openings and ramp-up of 2018 renovations.

During the quarter we continued the very important and intensive work on the five year plan intitiatives in all operational areas, buidling for future growth.

The growth of the company is also relying on new signings and I am very pleased with the signing of close to 9,400 rooms year-to-date, which is well ahead of plan and now targets to over achieve the record threshold of 10,000 in the year.

In the beginning of October we excercised our rights to acquire full ownership in prizeotel. The prizeotel team has done a fantastic job over the past few years growing the pipeline to four hotels in operation and 16 under development in strategic German-speaking countries.

Federico J. González, President & CEO


Presentation of the Q3 Results

On November 6, 2019 at 10:00 CET, a combined telephone conference and live webcast (in English) concerning the report will be presented by the President & CEO, Federico J. González and CFO, Sergio Amodeo. To follow the webcast, please visit https://www.radissonhospitalityab.com/investors.

To access the telephone conference, please dial:

Belgium, Local                    +32 (0)2 400 98 74
Belgium, Free                      0800 48740
France, Local:                      +33 (0)176 700 794
France, Free:                       0805 103 028
Norway, Local:                     +47 2396 0264
Norway, Free:                      800 51874
Sweden, Local:                    +46 (0)8 506 921 80
Sweden, Free:                     0200 125 581
UK, Local:                             +44 (0)844 571 88 92
UK, Free:                              0800 376 79 22
USA, Local:                          +1 163 151 074 95
USA, Free:                            1 866 966 13 96
Standard international       +44 (0)207 192 80 00

Confirmation code: 9197318. For a replay of the conference call please visit https://www.radissonhospitalityab.com/investors.

Financial Calendar

Q4 2019 results: February 25, 2020

For Further Information, Contact

Sergio Amodeo
CFO
sergio.amodeo@radissonhotels.com

Avenue du Bourget 44
B-1130 Brussels
Belgium
Tel: +32 2 702 9200


Website: www.radissonhospitalityab.com

About Radisson Hospitality AB (publ)

Radisson Hospitality AB (publ) is focused on hotel management and operates the core brands Radisson Blu and Park Inn by Radisson, as well as Radisson RED, an upscale “lifestyle select” brand inspired by the millennial lifestyle, and Radisson Collection, a premium lifestyle collection of exceptional hotels located in unique locations. Radisson also holds 49% in prizeotel, a young hotel chain in the economy segment.

The portfolio consists of 387 hotels, with 85,101 rooms, in operation and 126 hotels, with 25,066 rooms, under development in 80 countries across Europe, the Middle East and Africa.

Radisson’s strategy is to grow with an asset-right approach, balancing management and franchise contracts with selected lease contracts. Management and franchise contracts offer a higher profit margin and more stable income streams and lease contracts allow Radisson to complete their presence in Mature markets.

Radisson is a member of Radisson Hotel Group. For more information, visit www.radissonhospitalityab.com.

Download  Radisson Hospitality AB’s Q3 2019 report below

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

LIDDS Liproca® Depot Phase IIb study results presented at EMUC19 showing both primary and secondary endpoints being met16.11.2019 10:10:00 CETPress release

UPPSALA, SWEDEN – LIDDS AB (publ) Phase IIb clinical data from the LPC-004 prostate cancer study on LIDDS Liproca® Depot were presented today in an oral session at the 11th European Multidisciplinary Congress on Urological Cancers, EMUC19. The study met both its primary and secondary endpoints as well as demonstrated that a larger proportion of intermediate risk patients, which is the Liproca Depot target group, are PSA responders. The presentation can be accessed through LIDDS webpage and are also attached to this release. The phase IIb results from the LPC-004 prostate cancer study was presented as “Late Breaking News” at EMUC in Vienna on November 16, 2019 by Professor Laurence Klotz, a world leading expert in Active Surveillance of prostate cancer patients. Professor Klotz was one of the LPC-004 study investigators and is Professor at the University of Toronto Division of Urology at the Sunnybrook Health Sciences Centre in Canada. The preliminary data recently released from the pha

AMG Advanced Metallurgical Group N.V. Completes Acquisition of International Specialty Alloys15.11.2019 23:30:00 CETPress release

Amsterdam, 15 November 2019 --- AMG Advanced Metallurgical Group N.V. ("AMG", EURONEXT AMSTERDAM: "AMG") has finalized the acquisition of the assets of International Specialty Alloys ("ISA"), a leading U.S. producer of titanium master alloys and other binary alloys for the aerospace market, from Kennametal, Inc. The acquisition was previously announced on October 9, 2019 and closed and became effective today. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation, infrastructure, energy, and specialty metals & chemicals end markets. AMG Critical Materials produces aluminum master alloys and powders, ferrovanadium, natural graphite, chromium metal, antimony, lithium, tantalum, niobium and silicon metal. AMG Technologies produces titanium aluminides and titanium alloys for the aerospace market; designs,

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease15.11.2019 21:06:00 CETPress release

Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and the annual rate of days hospitalized (4 vs 6.87) in a 52-week study2 Approximately 100,000 people in the United States, most of whom are of African descent, have sickle cell disease3 Approval comes approximately two months ahead of FDA’s priority review action date, allowing Adakveo to be available to patients more quickly Basel, November 15, 2019 – Novartis announced today that the US Food and Drug Administration (FDA) approved Adakveo ® (crizanlizumab), previously known as SEG101, to reduce the frequency of vaso-occlusive crises (VOCs), or pain crises, in adult and pediatric patients aged 16 years and older with sickle cell disease.4 Adakveo represents the first FDA-approved medicine in sickle cell disease that binds to P-selectin –a cell adhesion protein that plays a central r

SFL - Invitation to Presentation of Q3 2019 Results15.11.2019 20:06:00 CETPress release

SFL Corporation Ltd. ("SFL" or the “Company”) (NYSE: SFL) plans to release its preliminary financial results for the third quarter of 2019 on Thursday, November 21, 2019. SFL plans to host a conference call and webcast for all stakeholders and interested parties on Thursday, November 21, 2019 at 10:00 AM (EST) / 4:00 PM (CET). Relevant material will be available from the Investor Relations section of the Company’s website at www.sflcorp.com on the same day. In order to listen to the presentation you may do one of the following: A: Webcast Visit the Investor Relations section of the Company’s website at www.sflcorp.com and click on the link to "Webcast". The webcast with slideshow will be played live from this platform. To listen to the conference call from the website, you need to have installed Windows Media Player, and you need to have a sound card on your computer. B: Conference Call Participants dial-in details: US Toll Free telephone number +1 866 966 1396 International Dial-in te

Cavotec’s Nomination Committee ahead of Annual General Meeting 202015.11.2019 18:00:00 CETPress release

The Nomination Committee of Cavotec SA (“Cavotec”) consists of members appointed by Cavotec’s Board of Directors, in accordance with Cavotec's Internal Regulations. The composition of the members of the Nomination Committee presented below is in line with the recommendations of the Swedish Corporate Governance Code. The main purpose and responsibility of the Nomination Committee is to present proposals for the election and remuneration of the Chairman and the Board of Directors as well as the Auditors to the Annual General Meeting 2020. The Board of Directors has decided that the four largest shareholders and the Chairman of Cavotec’s Board of Directors shall be represented in the Nomination Committee. On 31 October 2019, the four largest shareholders recorded in the company’s share register were Bure Equity AB (27.1% of the vote), AP4 (9.8% of the vote), Nomina SA (8.1% of the vote) and Founding Shareholders (Stefan Widegren, Lars Hellman and Peter Brandel with families) (11.9 % of th

Touax: Nine-Month Revenue From Activities: +4.9%15.11.2019 17:45:00 CETPress release

PRESS RELEASE Paris, 15 November 2019 – 5.45 p.m. YOUR OPERATIONAL LEASING SOLUTION NINE-MONTH REVENUE FROM ACTIVITIES: +4.9% Revenue 1 up 1.4% in the third quarter of 2019, Revenue up 4.9% over the first nine months of the year (+1.5% at constant scope and currency) validating the group’s strategic objectives ANALYSIS OF REVENUE FROM ACTIVITIES Q3 2019 revenue totalled €40.1 million vs. €39.6 million in Q3 2018, an increase of 1.4%. Over the first nine months of the year, revenue from activities totalled €119.6 million (€115.7 million at constant scope and currency), up 4.9% compared to the same period in 2018. Revenue from leasing activities amounted to 99.8 million euros (96.8 million euros at constant scope and currency) at 30 September 2019, including a 10% increase in the Leasing Revenue on owned equipment (36.9 million euros). Leasing Revenue from leasing activities stood at 99.9 million euros in the first nine months of 2018. Sales rose to €19 million (€14.2 million at constant